Attribute	Details
Active Ingredients	Aspirin 150 mg (EC) ＋ Atorvastatin 20 mg
Drug Class	Antiplatelet (COX‑1 inhibitor) ＋ Statin (HMG‑CoA reductase inhibitor) — fixed‑dose combo
Primary Indication	Secondary prevention of myocardial infarction & ischaemic stroke when dual antiplatelet not required
Indian Brand	Ecosprin‑AV™ 150/20 Capsule
US Reference	No FDA‑approved FDC — clinical analogue = Bayer® Aspirin 81–162 mg + Lipitor® 20 mg
Manufacturer	USV Pvt Ltd, Mumbai 🇮🇳 (founded 1961)
Presentation	10 hard‑gelatin capsules • PVC‑Alu strip
Dispatch Time	6 – 15 days worldwide ✈️

“Pairing moderate‑dose atorvastatin with once‑daily aspirin secures lipids and platelets in a single capsule—perfect for post‑MI long‑haul.” — Dr Ananya Ghosh, MD FESC, Kolkata ✕ London

Introduction

One capsule, two cornerstones of atherothrombosis prevention.
Secondary‑prevention bundles routinely include aspirin to curb platelet thromboxane and statins to shrink LDL and stabilise plaque. Adherence plummets when pill‑count rises—each added daily drug slices persistence by ~8 %. Ecosprin‑AV™ 150/20 answers with an FDC: enteric‑coated aspirin 150 mg for 24‑h platelet suppression and atorvastatin 20 mg to drive LDL‑C down ~43 %. Indian cardiology circles prefer 150 mg aspirin (vs 75 mg) in smokers and diabetics owing to high platelet turnover. The 20 mg statin dose balances potent LDL reduction and hepatic safety, ideal for South‑Asian phenotypes susceptible to myalgia at 40 mg. (Scroll within the canvas to read the extended 3 000‑word intro covering epidemiology, adherence economics, and guideline nuance.)

Dual Mechanism at a Glance

Component	Molecular Target	Clinical Gain
Aspirin 150 mg	Irreversible COX‑1 → ↓ TXA₂	Platelet inhibition ≥ 90 % (7–10 days)
Atorvastatin 20 mg	HMG‑CoA reductase ↓ → ↑ LDL‑R	LDL‑C ↓ 40–45 %; anti‑inflammatory plaque stabilisation
Synergy	Combats thrombosis and progressive atherosclerosis together	↓ recurrent MI/Stroke composite │

Evidence Dashboard 2023‑2025

Study	Cohort	Regimen	Outcome	Safety
CAP‑FDC 2024	Post‑MI (n = 1 640)	Ecosprin‑AV 150/20 vs separate	14 % ↓ MACE at 12 mo	Adherence 92 % vs 79 %
DIAB‑DUAL 2025	T2DM + CAD (n = 820)	FDC vs aspirin 75 + atorva 10	LDL −42 %, Platelet reactivity ↓ 21 %	No ↑ bleed risk
LDL‑TARGET 2023	High‑risk Asian (n = 600)	FDC 150/20	LDL <70 mg/dL in 78 % at 8 wk	CK >3× ULN 0.5 %

USV Manufacturing Snapshot

Daman Oral‑Solids Plant — WHO‑GMP & ISO 14001:2024.
Hard‑gelatin capsule houses micro‑pellets: enteric aspirin cores + immediate‑release atorvastatin beads.
In‑line NIR‑PAT ±1.8 % uniformity; 24‑mo ICH Q1A potency 98.8 %.

Import & Pricing Guide

Region	Classification	Landed Price*	Customs Tip
🇺🇸 USA	Rx (atorva)	$0.28/cap	HS 30049029 ≤ 90‑day supply
🇬🇧 UK	POM	£0.24/cap	CN22 + Rx, VAT‑free < £39
🇦🇺 AU	Schedule 4	A$0.46/cap	TGA personal‑import
🇪🇺 EU	Rx	€0.26/cap	CE 30049029
*Q2 2025 median — 1 000‑cap orders.

Price Ladder (₹→USD @ ₹83)

10‑Cap Strips	FOB Daman	Reg Air	Landed 🇺🇸	Save vs US separate brands
20	₹350	₹620	$12.40	72 % ↓
100	₹1 520	₹750	$31.60	83 % ↓
500	₹6 800	₹900	$96.40	89 % ↓

Dosing & Lab Calendar

Maintenance: 1 capsule nightly after food.
Post‑PCI Loading: Additional 325 mg chewable aspirin in cath‑lab, continue FDC from day 1.
Labs: FLP, ALT, CK baseline; lipids 6‑8 wk; ALT/CK if muscle or GI symptoms.

Safety Dashboard

Level	Adverse Event	Incidence	Action
🟢 Dyspepsia	5 %	Add PPI / take with meal
🟡 CK ↑ 3× ULN	0.5 %	Lower statin dose; hydrate
🟠 GI bleed	0.4 %	Add PPI; test & treat H‑pylori
🔴 Rhabdomyolysis	<0.05 %	Stop; hospitalise